Clinical Investigate Of Combination Of Docetaxel And Cisplatin In The Treatment Of Patients With Non-small Cell Lung Cancer

Objective To evaluate the efficiency and toxicities of the combination of docetaxel and cisplatin in the treatment of patients with non-small cell lung cancer (NSCLC) . Methods Sixty patients with locally advanced (stage III) or metastatic (stage IV) NSCLC were enrolled into the study. The patients received docetaxel 35 mg/ m2 on day1, and cisplatin 75 mg/ m2 on day 1 or days divided into l-3of a 21-day cycle. Each patient should complete two cycles. Results An objective response rate was obtained in 44 % of 60 patients (two complete and 25 partial response), whereas 24 patients had stable disease and 9 patients were progressive. The response rate was 44 % in the initial patients, and 41 % in the retreated patients. No significant difference existed between the two groups ( p> 0.05). The main toxicities were leukopenia (17.8 % in grade III+IV) and thrombocytopenia (12.8 % in grade III+IV) . Conclusion The combination of docetaxel and cisplatin is a feasible, reduced Toxicities, well-tolerated and active scheme treatment of NSCLC.